SMG1 divergent transcript (SMG1-DT)

"Divergent transcription" refers to the widespread phenomenon in mammals where transcription initiates bidirectionally from gene promoters, producing both the main (sense) gene transcript and usually a noncoding, antisense RNA known as a divergent or upstream antisense transcript[4][5]. "SMG1 divergent transcript" most likely designates a long noncoding RNA transcribed in the opposite direction from the promoter of the SMG1 gene. The biological functions of many divergent transcripts are unclear, but they are often thought to play regulatory roles, modulate chromatin state, or serve as proto-genes in gene evolution[4][5]. There is no evidence that the "SMG1 divergent transcript" is a protein, receptor, enzyme, or other classical drug target, nor is there evidence that it plays a direct role as a biomarker or in disease pathogenesis. References to "SMG1 divergent transcript" in gene databases or expression datasets indicate its position or expression, not a validated therapeutic target. If you intended the SMG1 protein (a kinase with roles in nonsense-mediated mRNA decay and stress response), that is a distinct and well-characterized molecular target, but “SMG1 divergent transcript” refers instead to a noncoding RNA and should not be treated as a target in the classic sense[1][4][5].